Press, Oliver W <br/><br/>
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Dec 2013 
 - 6624-32 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-13-1120  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Clinical Trials, Phase III as Topic<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Hemoglobins--metabolism<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lymph Nodes--pathology<br/>Lymphoma, Follicular--blood<br/>Middle Aged<br/>Multivariate Analysis<br/>Organ Size<br/>Prednisone--administration & dosage<br/>Prognosis<br/>Proportional Hazards Models<br/>Rituximab<br/>Vincristine--administration & dosage<br/>Young Adult<br/>beta 2-Microglobulin--blood